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of effector NK cells, irrespective of GM co-administration. 
These immune-potentiating effects were counterbalanced by 
increased IL-10 production by T cells and significantly higher 
levels of FoxP3 and CTLA4 in regulatory T cells (Tregs) with 
correspondingly higher suppressive activity in the SLN. Nota-
bly, CpG ± GM-administered patients showed significantly 
lower numbers of SLN metastases (saline: 4/9, CpG + GM: 
1/9, CpG: 0/10, p = 0.04). These findings indicate that i.d. 
delivery of low-dose CpG ± GM potentially arms the SLN of 
early-stage melanoma patients against metastatic spread, but 
that antitumor efficacy may be further boosted by counteract-
ing the collateral activation of Tregs.
Keywords Immunotherapy · Melanoma · Sentinel lymph 
node · CpG · GM-CSF · Regulatory T cells
Abbreviations
BDCA3  Blood dendritic cell antigen 3
CFSE  Carboxyfluorescein diacetate succinimidyl ester
CM  Complete medium
LAP  Latency-associated peptide
MAA  Melanoma-associated antigens
pDC  Plasmacytoid DC
SLN  Sentinel lymph node
SNP  Sentinel lymph node procedure
Tact  Activated T cells
Th1/Th2  Type 1/2 T helper
Tregs  Regulatory T cells
Introduction
Cutaneous melanoma is the most aggressive type of skin 
cancer, and its incidence is increasing worldwide. Once 
melanoma spreads beyond its primary site, prognosis 
Abstract Impaired immune effector functions in the mela-
noma sentinel lymph node (SLN) may allow for early meta-
static events. In an effort to determine the optimal way to 
strengthen immune defenses, 28 clinical stage I–II mela-
noma patients were randomized in a 3-arm Phase II study to 
receive, prior to excision and sampling of the SLN, i.d. injec-
tions of saline or low-dose CpG-B (CpG), alone or combined 
with GM-CSF (GM), around the melanoma excision site. We 
previously described the combined administration of these 
DC-targeting agents to result in activation and recruitment of 
potentially cross-presenting BDCA3+ DCs to the SLN. In this 
report we describe the effects on effector and regulatory T and 
NK cell subsets. Local low-dose CpG administration resulted 
in lower CD4/CD8 ratios, Th1 skewing, increased frequencies 
of melanoma-specific CD8+ T cells and possible recruitment 
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is very poor [1]. Therefore, in early-stage melanoma 
patients, an effective adjuvant treatment to counter meta-
static spread would be highly valuable. Melanoma is also 
one of the most immunogenic tumors. Tumor-reactive T 
cells are already detectable in the blood and TDLN in 
early stages of tumor development [2]. In recent years, 
it has become increasingly clear that melanoma evades 
and suppresses the immune system, thereby preclud-
ing an effective antitumor response and hampering the 
effect of cancer immunotherapy [3, 4]. As professional 
APCs and prime orchestrators of the innate and adaptive 
immune response, dendritic cells are obvious targets of 
melanoma-induced immune suppression [5]. When sup-
pressed, they prevent an effective antitumor immune 
response and promote tolerance to melanoma-associated 
antigens (MAA). The first-line TDLN, the sentinel lymph 
node (SLN), takes the brunt of the melanoma-associated 
immune suppression, making it in effect an “immune-
privileged site” with the ability to assert and maintain 
a state of systemic tolerance to MAA [3, 6]. Impaired 
immune effector functions in the SLN most likely con-
tribute to the early metastatic events that are associated 
with melanoma.
The sentinel lymph node procedure (SNP) presents a 
unique translational setting to study adjuvant immune ther-
apies in vivo [7]. To assess the functional immune status 
of the SLN, we developed a previously reported sampling 
technique whereby viable immune effector cells can be 
obtained without interfering with standardized diagnostic 
procedures [8]. By scraping the surface of bisected SLN, 
flow cytometric analysis of myeloid and lymphocytic sub-
sets and expansion of functional T cells can be achieved, 
while allowing regular lengthwise lamellar sampling of the 
whole SLN for immunohistochemical assessment of tumor 
involvement. The feasibility and non-interference with 
diagnostic outcome were subsequently confirmed by others 
[9].
In previous work we investigated the applicability of i.d. 
administration of GM-CSF or CpG in early-stage mela-
noma patients to reverse melanoma-induced immune sup-
pression and mount an effective antitumor response. Both 
the targeting of conventional myeloid DCs by GM-CSF 
and plasmacytoid DCs (pDCs) by CpG elicited impressive 
activation, maturation and recruitment of DCs to the SLN 
and a subsequent increase in melanoma-specific CD8+ 
T cells, supporting the utility of these agents as adjuvant 
treatment in early-stage melanoma patients [10–13]. Since 
both compounds have been shown to interact synergis-
tically to induce an antigen-specific antitumor immune 
response in murine models [14, 15] and proved to be clini-
cally safe [16], we combined CpG and GM-CSF, both at 
lower doses than before to minimize side effects (1 mg and 
100 μg, versus 8 mg and 3 µg/kg/day for 4 consecutive 
days, respectively), and studied their effects in a rand-
omized Phase II trial in comparison with administration of 
low-dose CpG alone or saline.
As recently reported by us [17], this combined adminis-
tration resulted in activation of the full range of DC subsets 
and recruitment of potentially cross-presenting BDCA3+ 
DCs to the SLN. Here we report on the subsequent effects 
on the T and NK effector cells. Overall, our data point to 
dominant effects of CpG over GM-CSF at the adminis-
tered doses. Beside lowering CD4/CD8 ratios, skewing to a 
type-1 T cell response profile, possibly inducing NK effec-
tor trafficking and increasing MAA-specific CD8+ T cell 
frequencies, we show that CpG has clear collateral suppres-
sive effects in vivo, specifically by activating regulatory T 
cells (Tregs).
Materials and methods
Patients, clinical procedures, and cell sampling
From September 2006 until May 2008, 28 patients were 
included in this single-blinded Phase II study and ran-
domly assigned to receive preoperative local administra-
tion of either GM-CSF (Leukine, Berlex Laboratories Inc. 
Montville, NJ) and synthetic CpG-B (PF-3512676, Coley 
Pharmaceutical Group, Inc., Wellesley, MA), CpG-B alone 
or saline (NaCl 0.9 %). All patients were clinically diag-
nosed with stage I/II melanoma, according to criteria of the 
American Joint Committee on Cancer, and were scheduled 
to undergo SNP. Inclusion criteria were as described pre-
viously [13]. The Institutional Review Board of the VU 
University Medical Center approved the study, and written 
informed consent was obtained from each patient prior to 
treatment.
All patients received 4 ml i.d. injections directly into 
the scar of the primary melanoma excision, 7 and 2 days 
before SNP; injections consisted of either a combination 
of 1 mg CpG and 100 μg of GM-CSF, 1 mg CpG or 4 ml 
plain saline. Heparinized blood was drawn prior to the 
first injection (t = −7) and on the day of the SNP (t = 0). 
Viable PBMCs were isolated and cryopreserved for further 
analysis as previously described [12]. One week after the 
first injection all patients underwent SNP and reexcision 
of the primary melanoma site as described [18]. SLNs 
were collected in sterile ice-cold IMDM supplemented 
with 25 mM HEPES buffer (BioWhittaker, Verviers, Bel-
gium) with 10 % FCS, 50 IU/ml penicillin–streptomycin, 
1.6 mM l-glutamine and 0.05 mM β-mercaptoethanol 
[i.e., complete medium (CM)]. Viable cells were scraped 
from the SLN using a previously described method [8]. 
SLN cells were washed twice in CM, counted, and further 
processed.
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T cell expansion
T cells from all SLN were expanded as described previ-
ously [11]. Briefly, cells were incubated for 1 h on ice with 
2 µg anti-CD3 and 0.4 µg anti-CD28 per 106 cells (clones 
16A9 and 15E8, kindly provided by Dr. René van Lier, San-
quin, Amsterdam, the Netherlands) in 100–200 µl CM with 
5 % FCS. After incubation and washing, cells were placed 
in 24-well plates (Greiner Bio-One) pre-coated with affin-
ity-purified goat antimouse Ig (1:100; DAKO) in CM with 
10 % FCS at a concentration of 106/ml/well for 1 h at 4 °C. 
Cells were subsequently cultured for 48 h in a humidified 
5 % CO2 incubator at 37 °C. After 24 h 100 μl supernatant 
from each well was stored for T cell cytokine analysis (see 
next paragraph). After 48 h, cells were resuspended and the 
contents of each well were divided over four new uncoated 
wells at 250 µl/well. To each well, 750 µl CM supple-
mented with 14 IU/ml recombinant human IL-2 (Sanquin) 
was added, resulting in a final concentration of 10 IU/ml 
rhIL-2. Cells were cultured for another 5 days, after which 
they were harvested and counted. All SLN T cells under-
went two expansion cycles. Finally, the expanded T cells 
were harvested and cryostored for functional analysis at a 
later date.
T cell cytokine profiling
Supernatants from the 24-h polyclonal T cell ex vivo 
expansion cultures were analyzed using the Type 1/2 T 
helper (Th1/Th2) Cytometric Bead Array kit for flow cyto-
metric detection of IL-2, IL-4, IL-5, IL-10, TNF-α and 
IFN-γ, following the manufacturer’s instructions and using 
Cytometric Bead Array analysis software (BD Biosciences, 
San Jose, CA).
Expanded T cells were used for analysis of intracellular 
T cell cytokines. 1 × 106 cells were stimulated for 4½ h 
in a humidified 5 % CO2 incubator at 37 °C with 50 ng/
ml PMA and 500 ng/ml ionomycin in the presence of 
1:500 Golgiplug (BD Biosciences) resuspended in Yssels 
medium at a concentration of 2 × 106/ml. After stimulation 
cells were washed and stained.
Flow cytometry
Freshly isolated SLN cells, expanded SLN T cells or 
thawed PBMCs were directly stained with antibodies 
labeled with either FITC, PE, PE-CY5.5, PerCP-CY5.5 
or allophycocyanin and analyzed by flow cytometry at 
100,000 or 200,000 events per measurement, as previ-
ously described [8, 9]. Monoclonal antibodies against 
CD3, CD4, CD8, CD56, CD19, CD25 (BD Biosciences) 
and latency-associated peptide (LAP) (R&D Systems Inc. 
Minneapolis, MN) with matching isotype control anti-
bodies were used. Intracellular FoxP3 staining was done 
using the eBioscience (San Diego, CA) PE-antihuman 
FoxP3 staining set following the manufacturer’s instruc-
tions. CTLA4, IFN-γ, TNF-α, IL-2, IL-4 and IL-5 were 
stained intracellularly using the Cytofix/Cytoperm Kit 
with GolgiStop (BD Biosciences) as described [19]. LAP 
staining was performed as described [20]; CD4- and 
CD25-enriched and CD4- and CD25-expanded T cells 
were stimulated for 48 h with anti-CD3 and anti-CD28 
mAbs (both at 1 μg/ml) in the presence of 10 IU IL-2 
after which they were stained according to the published 
protocol [20].
Suppression assay
Tregs were enriched from expanded SLN T cells and PBMC. 
After resuspending cells in PBS + 0.5 %BSA + EDTA an 
untouched CD4 MACS isolation was performed accord-
ing to the manufacturer’s protocol (Miltenyi Biotec, Ber-
gisch Gladbach, Germany), routinely achieving purities 
of approximately 95 %. In addition, a CD25 magnetic 
bead-mediated isolation was performed twice to select for 
CD4+CD25hi cells (Miltenyi). Average Treg purity after 
enrichment, defined as % CD3+CD4+CD25hiFoxP3+ 
cells of total T cells, was 32.9 ± 4 and 43.9 ± 3.1 % from 
expanded SLN T cells and PBMC, respectively. Purity did 
not differ significantly between the three groups (p = 0.62 
and p = 0.54 for SLN and PBMC, respectively). Enriched 
Tregs were resuspended in CM at 0.5 × 10e6/ml.
Effector cells were isolated from two different buffy 
coats. After untouched CD4 isolation, CD25+ cells were 
depleted using CD25 magnetic beads according to the 
manufacturer’s protocol (Miltenyi). Until use in suppres-
sion assays, CD4+CD25−/low cells were cryostored. After 
thawing, CD4+CD25−/low effector cells were resuspended 
in PBS + 0.1 % BSA at 1 × 10e6 cells/ml and incubated 
for 7 min at 37 °C with 3 µM carboxyfluorescein succin-
imidyl ester (CFSE). Cells were washed and resuspended 
in CM for 15 min to stabilize CFSE staining. After a final 
wash step, cells were resuspended in CM at 0.5 × 10e6/ml 
as previously described [21].
5 × 104 Tregs were cultured at a 1:1 ratio with alloge-
neic CD4+CD25−/low cells. The cells were stimulated with 
anti-CD3 mAb (1 μg/ml) and anti-CD28 mAb (1 μg/ml) 
in the presence of 10 IU IL-2 in 96-well round-bottom 
plates. After 3 days, proliferation (i.e., CFSE dilution) of 
responder cells was analyzed by FACS. Assays were per-
formed in triplicate or duplicate, and suppression was cal-
culated as the average decrease of proliferation of effector 
cells compared to positive controls (i.e., effector cells with-
out added Tregs).
408 Cancer Immunol Immunother (2016) 65:405–415
1 3
Tetramer staining
PE-labeled HLA-A2 tetramers (kindly provided by Dr. 
Ton Schumacher, Netherlands Cancer Institute, Amster-
dam, the Netherlands) presenting melanoma-associated 
epitopes Gp100154–162, Gp100209–217, Gp100280–288, MAGE-
A3271–279, MART-126–35, NY-ESO157–165 and TYR369–377 
were used to detect MAA-specific CD8+ T cells. Gp100 
tetramers were pooled. Tetramer staining was performed as 
previously described [22].
Statistics
Overall differences between the three patient groups in terms 
of patient and SLN characteristics and immune parameters 
were analyzed using the Kruskal–Wallis test. The post hoc 
multiple comparison Dunn’s test was used to analyze dif-
ferences between two patient study groups. For differences 
between two groups the Mann–Whitney test was used. Cor-
relations were determined using the Pearson r test. Differ-
ences were considered statistically significant when p < 0.05.
Results
Patient characteristics
A total of 28 patients with clinical stage I–II melanoma 
were included in this study. Patients were randomly 
assigned to one of three test groups: receiving two i.d. 
injections of (1) saline, (2) CpG-B (1 mg) and GM-CSF 
(100 μg) (CpG + GM) or 3) CpG-B only (1 mg) (CpG). 
Injections were administered 7 and 2 days prior to SNP. 
Adverse effects of CpG ± GM were transient and mild 
flu-like symptoms [17]. After pathological examination, 5 
of 28 SLNs contained tumor cells, corresponding to patho-
logically confirmed stage III disease. Four of these stage III 
patients had received saline, resulting in a remarkable and 
statistically significant difference in lymph node positivity 
between groups (p = 0.04). Of these lymph node metasta-
ses, two had a diameter greater than 2 mm, one in the saline 
and the other in the CpG + GM group. All patients but one 
with a positive SLN underwent an additional lymph node 
dissection, and all additional nodes were found to be tumor 
negative. The one patient for whom a watchful waiting 
policy was followed harbored a micrometastasis, but devel-
oped a clinically detectable regional lymph node metasta-
sis 8 months after SNP, whereupon a delayed completion 
lymph node dissection was performed. HLA-A2 status was 
determined by flow cytometry to enable testing of specific 
CD8+ T cell frequency for a panel of melanoma-derived 
CD8+ T cell epitopes. Patient characteristics are summa-
rized in Table 1.
Lymphocyte subsets and T cell cytokine profiles: CD4/
CD8 shift and Th1 skewing
No significant differences in frequencies of B and 
NK cells from freshly isolated SLN cells were found 
between patient groups. However, in both CpG test 
groups we observed significantly decreased frequencies 
of CD4+ T cells leading to significantly lower CD4/CD8 
ratios in the CpG + GM group. The expression levels of 
the activation markers CD25, CTLA4 and FoxP3 in acti-
vated CD4+ T effector cells (Tact, i.e., with intermedi-
ate CD25 and FoxP3 expression levels) in the SLN were 
slightly, but not significantly, higher in the CpG test 
groups (Table 2).
To determine the effects of local CpG or CpG + GM 
administration on T cell skewing in the melanoma SLN, we 
measured Th1 and Th2 cytokines in supernatants of freshly 
isolated SLN cells ex vivo, which were stimulated overnight 
by immobilized anti-CD3 and anti-CD28. No clear differ-
ences were observed between the CpG and CpG + GM 
groups. However, compared to the saline group, CpG ± GM 
administration led to increased production of all measured 
cytokines and resulted in significantly skewed Th1 profiles 
as determined by IFN-γ/IL-4 ratios (Fig. 1a).
Table 1  Patient and sentinel 
lymph node characteristics
† By Kruskal–Wallis test
Bold value indicates statistical difference
Saline CpG + GM CpG p†
Gender (male:female) 4:5 4:5 6:4 0.74
Age (mean ± SD) 47 ± 12 50 ± 12 58 ± 12 0.16
Breslow thickness [mean ± SD (mm)] 1.67 ± 0.55 2.19 ± 1.37 1.73 ± 0.96 0.67
Tumor-positive SLNs 4/9 1/9 0/10 0.04
Additional lymph node dissection 3/9 1/9 0/10 0.12
Time from primary excision to SNP [mean ± SD (days)] 45 ± 19 47 ± 9 47 ± 20 0.77
HLA-A2 4/9 5/9 8/10 0.28
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A statistically nonsignificant trend was observed for 
the association of type-1 skewed profiles with CpG ± GM 
administration in CD4+ and CD8+ T cells as detected 
by intracellular cytokine expression after expansion 
(Fig. 1b). There was a general lack of detectable type-2 
cytokine expression. Although consistent with the consid-
erably (10- to 100-fold) lower concentrations of released 
Th2 cytokines in pre-expansion populations (as shown in 
Fig. 1a), this might also have resulted from the expansion 
procedure.
CpG/GM effects on NK cells
In contrast to saline administration, after CpG as well as 
CpG + GM administration NK cell frequencies in the 
peripheral blood on average decreased (Fig. 2a). Although 
this difference was limited and did not reach statistical sig-
nificance, the changes in NK cell frequencies in the periph-
eral blood correlated significantly (p < 0.01) with frequen-
cies of NK cells in SLNs of CpG ± GM-administered 
patients, suggesting a recruitment of NK cells to the SLN 
Table 2  Sentinel lymph node lymphocyte subset frequencies
* p < 0.05 versus saline by Kruskal–Wallis test with Dunn’s post-test
a Indicated percentages are of measured SLN leukocytes
b Indicated percentages are of CD3+CD4+CD25int T cells
Bold values indicates statistical differences










B cells (%) NK cells  
(%)
T cells (%) CD4+ T cells 
(%)
CD8+ T cells 
(%)
Saline 14.2 1.25 77.9 66.5 8.8 8.9 3.87 5.41 2.30
Range 9.9–20 0.7–2.2 69–85 55–75 3.5–12 5.1–20 1.3–9.0 2.3–9.5 0.3–4.4
CpG + GM 16.7 1.56 70.9 51.8* 15.1 3.9* 6.36 5.60 1.08
Range 11–28 1.1–2.0 51–80 32–67 9.0–22 2.1–6.6 2.2–9.1 2.9–11 0.6–2.4
CpG 17.7 1.38 68.1* 52.5* 10.9 5.6 4.44 5.36 1.60
Range 6.9–35 0.7–2.2 52–78 36–60 5.2–16 2.4–10 1.6–8.0 2.7–8.0 0.4–3.3
Fig. 1  T cell cytokine profiles reveal CpG-associated Th1 skewing. a 
Cytokine secretion profiles and Th skewing (represented as the aver-
age of all IFN-γ/IL-4 ratios) of freshly harvested SLN T cells after 
in vitro stimulation. Means (in bar graphs with SEM) are shown. b 
Intracellular cytokine levels in expanded SLN CD4+ (top row) and 
CD8+ (bottom row) T cells after in vitro stimulation. Shown are per-
centages of cells positive for the indicated intracellular Th1 and Th2 
cytokines and Th skewing. *p < 0.05; **p < 0.01
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upon CpG ± GM administration (Fig. 2b). Although not sta-
tistically significant (p = 0.085), we observed a shift from a 
predominant CD56bright regulatory SLN NK cell population 
in the saline-administered group toward more CD56dim effec-
tor SLN NK cells in both CpG test groups (Fig. 2c). In the 
CpG + GM group, we found highly significantly (p < 0.01) 
elevated percentages of NK cells with surface expression 
of TRAIL compared to the saline as well as the CpG group 
(Fig. 2d), pointing to an essential role for GM-CSF in this 
up-regulation. Of note, the same held true for TRAIL expres-
sion on SLN T and B cells (data not shown).
Increased Treg activation in the SLN, but not 
in peripheral blood
Neither in freshly isolated SLN cells nor in the peripheral 
blood, differences in percentages of natural Tregs (nTregs, 
defined as CD3+CD4+CD25hiFoxP3+) were observed 
between patient groups (Table 2; data not shown for periph-
eral blood). There was, however, a clear and significant dif-
ference in levels of expression of FoxP3 and CTLA-4 in 
freshly isolated SLN Tregs between both CpG test groups 
and the saline control group (Fig. 3a). In contrast, FoxP3 
levels in Tregs isolated from peripheral blood (t = 0) 
were comparable between groups (MFI, saline: 197 ± 14, 
CpG + GM: 202 ± 126, CpG: 160 ± 75). In addition, in 
supernatants of freshly isolated SLN cells from both CpG 
test groups, we found elevated levels of IL-10 after over-
night stimulation by immobilized anti-CD3 and anti-CD28 
compared to the saline control group, reaching signifi-
cance for the CpG group (Fig. 3a). To assess suppressive 
functionality of Tregs, enriched fractions from PBMC and 
expanded SLN T cells were used. To obtain sufficient cells 
for functional testing of Treg activity we were forced to 
expand SLN T cells. Figure 3b shows representative Treg 
(CD25/FoxP3) staining after magnetic bead-mediated 
Treg enrichment from SLN and PBMC samples. Gener-
ally high CD25 levels in SLN Tregs resulted from their 
expansion and concomitant activation. Two representative 
suppression assays, one from a saline and the other from a 
CpG-administered patient, are shown in Fig. 3c. For com-
parison between groups we used the relative suppression of 
proliferation of CD4+CD25− target cells by CD4+CD25+-
enriched fractions from expanded SLN T cells and PBMC 
at a 1:1 ratio. Corresponding to the elevated IL-10 release 
and high expression levels of suppressive FoxP3 and 
CTLA-4 in unexpanded Tregs from the SLN we observed 
a statistically nonsignificant trend (p = 0.09) toward 
increased suppressive activity of Treg-enriched fractions 
from expanded SLN T cells in CpG-administered patient 
groups (Fig. 3d). In contrast, no difference in suppressive 
activity of Treg-enriched populations from peripheral blood 
was observed between patient groups, in keeping with the 
equivalent FoxP3 expression levels in these cells (Fig. 3d).
Fig. 2  CpG/GM effects on NK cells. a Absolute changes in percent-
ages of blood NK cells between t = −7 (pre-treatment) and t = 0 
(post-treatment) are shown. b Changes in peripheral blood NK cell 
frequencies for CpG ± GM-administered patients are significantly 
and reversely correlated to corresponding SLN NK cell frequen-
cies. c Shift from predominant regulatory CD56bright to more effec-
tor CD56dim NK cells in the melanoma SLN. Average CD56dim/
CD56bright ratios are shown for each group by box and whisker plot. 
d Surface TRAIL expression on SLN NK cells. *p < 0.05; **p < 0.01
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LAP is expressed on the cell surface of activated, but 
not resting Tregs, and has not only been shown to be use-
ful in the purification of Tregs from expansion cultures, 
but also as a marker of Tregs for immune-monitoring stud-
ies in patients treated with active immunotherapy [20, 
23]. We stained extracellular LAP after 48 h of anti-CD3/
anti-CD28-mediated stimulation of Treg-enriched fractions 
of expanded SLN T cells as previously described [20]. 
Figure 3e shows LAP expression in relation to FoxP3 and 
CD25 from a representative patient. Indeed, LAP+ Tregs 
were also highly positive for CD25 and FoxP3, in keep-
ing with their reported regulatory activity. We observed a 
statistically nonsignificant trend toward higher frequencies 
of LAP+ Tregs in the CpG and to a lesser extent in the 
CpG + GM group, as compared to the saline group 
(Fig. 3f), corresponding to the observed IL-10 release 
(Fig. 3a) and suppressive activity in these groups (Fig. 3d).
Increased melanoma‑specific CD8+ T cell frequencies 
in CpG + GM‑treated SLN
We determined CD8+ T cell frequencies against a panel 
of MAA by tetramer binding of HLA-A2+ patients with 
sufficient numbers of T cells expanded from the SLN sus-
pensions (Fig. 4a). We stratified tetramer-binding results 
according to SLN tumor status because, in accordance 
Fig. 3  Increased Treg activation and suppressive activity in SLN, 
but not in peripheral blood. a CTLA-4 and FoxP3 expression lev-
els [by mean fluorescence intensity (MFI)] in freshly isolated SLN 
Tregs and IL-10 secretion after stimulation of freshly harvested SLN 
T cells. *p < 0.05; **p < 0.01. b Representative Treg staining of 
CD25-depleted and CD25-enriched expanded SLN T cells and of T 
cells from the peripheral blood,  % Tregs are listed. c Representative 
suppression assays from a saline- and a CpG-administered patient. 
Gray bars show the percentage of proliferated CD4+CD25− effector 
cells in the presence of CD4+CD25+-enriched fractions of expanded 
SLN T cells at different ratios. d Closed bars indicate the suppressive 
activity of CD4/CD25-enriched, expanded SLN T cells for all three 
groups. Open bars indicate the suppressive activity of CD4/CD25-
enriched T cells from the peripheral blood at the same time point 
as SLN harvest (t = 0). Numbers of patients tested in the SLN and 
peripheral blood are, respectively: saline: 5/6, CpG + GM: 7/6, CpG: 
6/5. e Representative CD25/LAP and FoxP3/LAP staining after pre-
gating on CD3+CD4+ cells. f LAP expression of CD3+CD4+CD25+ 
cells from expanded SLN T cells. Average percentages of LAP with 
SEM are shown for each group. N = 4 in each group
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with previous reports [2], a trend (p = 0.07) toward higher 
tetramer-binding rates was found in tumor-positive SLN 
from saline-administered patients (Fig. 4a). Consistent with 
our previous studies of CpG or GM-CSF single administra-
tion [11, 12], we found significantly higher levels of MAA-
specific CD8+ T cell rates in tumor-negative SLNs of com-
bined low-dose CpG and GM-CSF-administered patients 
compared to the tumor-negative control group (Fig. 4b). 
Low-dose CpG only also resulted in higher tetramer 
response rates, but this did not reach statistical significance.
A tetramer response was considered positive when the 
frequency of CD8+ tetramer-binding T cells exceeded 
the mean tetramer response rate plus two times the stand-
ard deviation in the tumor-negative control group (i.e., 
28 tetramer+CD8+ T cells/105 CD8+ T cells). Positive 
responses are listed in Fig. 4a, b, showing that five out of 
seven evaluable CpG ± GM-treated patients showed a pos-
itive response (8/21 epitopes tested), while neither of the 
two evaluable tumor-negative control patients showed a 
positive response (0/7 epitopes tested).
Discussion
In previous studies of single i.d. administration of either 
GM-CSF or CpG, we found evidence for antimelanoma 
immune potentiation of the primary tumor site and its lym-
phatic drainage area through the boosting of tumor-specific 
CD8+ T cells [11, 12]. In the current study we monitored 
the effects of combined i.d. administration of low-dose 
GM-CSF and CpG and found a full-range activation of 
DC subsets in SLN (migratory and lymph node resident) 
and peripheral blood as well as a recruitment of BDCA3/
CD141+ DC subsets with cross-priming ability to the SLN 
[17]. In the current report we have endeavored to assess the 
functional consequences of this adjuvant treatment in terms 
of effector and regulatory lymphocyte activation. Except 
for the up-regulation of TRAIL after CpG + GM admin-
istration on lymphocyte subsets and NK cells, we did not 
observe obvious differences between CpG and CpG + GM 
administration. This seems contradictory to the reported 
synergy between these two agents [14, 15] and may be 
explained by the small size of our study groups. This lack 
of power also calls for caution in the interpretation of some 
of our other results. The monitoring of melanoma-specific 
CD8+ T cells in particular was hampered by the limited 
number of cells and HLA-A2-positive patients evaluable. 
Nevertheless, in concordance with our previous studies, we 
found significantly increased frequencies of MAA-specific 
CD8+ T cells in the SLN of low-dose CpG + GM-admin-
istered patients [11, 12]. Moreover, the apparent dominant 
effect of CpG over GM-CSF in terms of T cell activation 
corresponds to our previous findings for DC recruitment 
and activation [17].
Others have combined CpG and GM-CSF with mela-
noma-associated peptides for vaccination in patients with 
advanced (stage III–IV) melanoma and have shown it to 
be a safe and promising strategy, but with poor to moder-
ate clinical results, which were attributed to the presence 
of local regulatory responses and the exhausted phenotype 
of tumor infiltrating lymphocytes [16]. Although T cell 
exhaustion is believed to play a minor role in early-stage 
malignancies, regulatory responses may well be an impor-
tant hurdle for effective immunotherapy in early-stage 
melanoma [24, 25]. Therefore, beside monitoring the 
effector arm of the immune system, we were interested in 
Fig. 4  MAA-specific CD8+ T cells in the SLN. a MAA-specific 
tetramer+CD8+ T cell rates in the SLN of HLA-A2+ saline-adminis-
tered patients are shown for tumor-negative and tumor-positive SLNs. 
Each dot represents one melanoma-specific tetramer-binding CD8+ 
population. The cutoff threshold set for positive tetramer responses 
is shown as a dashed line. b MAA-specific tetramer+CD8+ T cell 
rates in tumor-negative SLNs for all three groups. Below both graphs 
response numbers relative to evaluated numbers of patients and 
epitopes are shown. *p < 0.05
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potentially suppressive effects of CpG and GM-CSF, par-
ticularly since recent evidence shows that CpG can induce 
IDO and STAT-3 expression in pDCs with collateral acti-
vation of Tregs [26–28]. In our previous study of single 
dose (8 mg) CpG administration we observed lower per-
centages of CD4+CD25hi SLN Tregs in CpG-administered 
patients [10]. In the current study of low-dose CpG ± GM, 
we found no differences in SLN Treg frequencies between 
groups. This apparent discrepancy might be attributable to 
the difference in dosing and timing of CpG administration, 
to higher numbers of SLN samples included in the analyses 
or to more accurate Treg analyses used in the current study 
(using freshly harvested T cells and consistently including 
FoxP3 in the gating strategy).
More importantly, we found that intradermal 
CpG ± GM administration led to significantly higher 
expression levels of CTLA-4 and FoxP3 (CpG + GM 
group only) in freshly isolated SLN Tregs and to a corre-
spondingly higher, but statistically nonsignificant, suppres-
sive activity of Treg-enriched fractions from expanded SLN 
T cells. In contrast, no differences in Treg activation and 
suppressive activity were observed in peripheral blood. To 
obtain sufficient cells for functional testing of Treg activity 
we were forced to expand T cells from SLN. It has previ-
ously been shown that the suppressive potential of Tregs is 
preserved after in vitro anti-CD3/anti-CD28 expansion [29, 
30]. Conversely, we found no evidence for an expansion-
induced increase in suppression, since expanded Tregs 
from PBMCs showed similar suppressive activity as their 
unexpanded counterparts in two parallel tests we performed 
(Suppl. Fig. 1). The recent identification of LAP as a means 
to identify highly suppressive Tregs in expanded or acti-
vated T cell populations [20, 31, 32] prompted us to moni-
tor its expression in our patients. The observed trend toward 
higher frequencies of LAP+ Tregs in expanded SLN T cells 
from CpG ± GM-administered patients might reflect their 
increased suppressive potential.
It cannot be excluded that in addition to nTregs, induced 
Tregs were involved in the increased suppressive activity of 
Tregs from CpG-conditioned SLNs. Induced Tregs are hard 
to distinguish from nTregs since no specific markers exist 
[33]. Their primary mode of action appears to be through 
the secretion of IL-10 (Tr1 cells, i.e., induced regulatory 
T cells) [34] or TGF-β (Th3 cells) [31]. An indication for 
the increased induction of Tregs after CpG administration 
is the significantly increased IL-10 release by freshly har-
vested T cells from the CpG-conditioned SLN. In addi-
tion, IFN-α strongly enhances IL-10-induced Tr1 differ-
entiation [35]. Although CpG-B is a relatively weak IFN-α 
inducer, we have demonstrated that it induced a systemic 
transcriptional IFN-α response signature in our patients 
[17]. Finally, the significantly elevated levels of CTLA-4 
in the SLN Tregs of CpG-administered patients could have 
contributed, via the proposed model of reverse signaling 
in pDCs, to the induction and activation of Tregs by IDO+ 
pDCs [36].
We observed a remarkably lower number of tumor-pos-
itive SLNs in the CpG ± GM-administered groups com-
pared to saline-administered patients (Table 1). We interpret 
this to result from an effective antitumor immune response, 
boosted by the locally applied CpG ± GM. This may seem 
unlikely (i.e., the elimination within 1 week of metastases 
that persisted or grew out between primary tumor excision 
and SLN procedure), however, recent studies have demon-
strated the ability of T cells, when properly unleashed, to 
rapidly clear even bulky tumors, and all metastases found 
in the SLN were clinically occult and often very small 
(<2 mm) [43]. As such, this observation would suggest that 
the increase in local suppressive markers after CpG ± GM 
administration does not outweigh the immune stimulatory 
properties of these agents. But, because this study was not 
powered to detect this unanticipated difference, it might be 
a mere coincidental finding. To exclude the possibility that 
the administration of CpG ± GM or the scraping procedure 
led to false-negative SLNs, we are closely monitoring the 
follow-up of all patients and, encouragingly, preliminary 
data point to prolonged recurrence-free survival of the 
intervention groups (Koster, van den Hout and colleagues, 
manuscript in preparation).
Because of the imbalance in SLN positivity, compari-
sons between groups at an immunological level might be 
biased. To make sure the observed immunological differ-
ences were not related to the presence of tumor cells we 
compared the immunological results from the CpG ± GM-
administered patients to SLN-positive and SLN-negative 
patients from the saline group (see Suppl. Fig. 2 for rep-
resentative examples). This clearly demonstrated that the 
immune stimulatory and regulatory effects on a T and NK 
cell level were related to CpG ± GM administration and 
not to the presence of tumor cells.
Our finding that CpG ± GM administration in melanoma 
patients enforces antitumor immunity through DC activa-
tion, a skewed Th1 response, and the boosting of CD8+ 
cytotoxic T cell responses is in keeping with previous obser-
vations in animal studies [14, 37]. Beside T cell immunity, 
an important role of NK cells, both in direct antitumor 
immunity and through shaping of the adaptive immune 
response via DC activation and editing, is becoming 
increasingly clear [38]. In murine models, tumor rejection 
after peritumoral injection of CpG was found to be depend-
ent on NK cell recruitment to the tumor site, which led to 
the induction of a tumor-specific CTL response via cross-
presentation by DCs [39, 40]. Some corroborating evidence 
is found in human studies: a phase II trial with subcutaneous 
CpG in metastatic melanoma patients showed that clinical 
benefit was associated only with NK cell cytotoxicity [41]. 
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In the present study we found circumstantial evidence for a 
CpG ± GM-induced recruitment of NK cells to the SLN, 
corresponding to murine studies in which more conclusive 
evidence for TLR-mediated NK cell recruitment could be 
obtained [40, 42]. Together with a trend toward more effec-
tor CD56dim NK cells after CpG ± GM administration 
and increased expression of TRAIL after CpG + GM, this 
points to increased tumoricidal activity of SLN NK cells.
Overall, we conclude that, although CpG ± GM-admin-
istered patients showed significantly lower numbers of SLN 
metastases, additional measures to minimize loco-regional 
Treg activity might optimize the clinical efficacy of CpG 
and GM-CSF as immune-potentiating agents for early-
stage melanoma patients.
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